2.2900
04-October-24 15:59:59
15 minutes delayed
Stocks
-0.0200
-0.87%
Today's range
2.2900 - 2.4200
ISIN
N/A
Source
NASDAQ
Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity
12 Mar 2024 08:38:26 By Nasdaq GlobeNewswire
Fractyl Health Appoints Samuel Conaway to Its Board of Directors, Bolstering New Product Commercial Expertise During Revita® Pivotal Clinical Trials
20 Feb 2024 08:38:00 By Nasdaq GlobeNewswire